Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial(s). ^[1]
• Oleogel-S10 (birch triterpenes) achieved complete closure of the target wound in 41.3% of patients within 45 days, compared to 28.9% in the control group.
• The relative risk for wound closure with Oleogel-S10 versus control gel was 1.44 (95% CI: 1.01-2.05; P = 0.013), indicating a statistically significant improvement in wound healing.
• The study population included patients with dystrophic, junctional, or Kindler EB, with target wounds of partial thickness lasting between 21 days and 9 months, sized 10-50 cm². However, no specific subgroup analysis based on EB types was reported.
• Adverse events (AES) were reported in 81.7% of patients treated with Oleogel-S10 and 80.7% of patients using the control gel. Most AEs were mild to moderate, with 4.6% being severe.
• The frequency and intensity of AEs were similar between the Oleogel-S10 and control gel groups, with no significant safety concerns or adverse effects specific to particular population types or subgroups noted.
• The study population included patients with dystrophic, junctional, or Kindler epidermolysis bullosa (EB), with target partial-thickness wounds lasting between 21 days and 9 months and sized 10-50 cm². The abstract does not provide further details on effectiveness or safety outcomes across different EB subtypes or other specific subgroups.